Disc Medicine, Inc. Common Stock
IRONDisc Medicine, Inc. (IRON) is a clinical-stage biopharmaceutical company focused on developing therapies for serious and rare hematologic diseases. The company aims to address unmet medical needs through innovative drug discovery and development, with particular emphasis on conditions related to iron metabolism and anemia.
Company News
Disc Medicine reported promising results from its Phase 2 trial of DISC-0974 for treating anemia in myelofibrosis patients, demonstrating substantial hematologic responses across different patient subgroups and transfusion statuses.
Bain Capital Life Sciences Investors completely sold its entire stake in Disc Medicine during Q3 2025, disposing of 583,500 shares worth approximately $30.90 million, signaling a potential shift in institutional sentiment towards the biotech company.
Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential drug commercialization and research efforts.
The article discusses upcoming events and earnings reports that investors should watch, including the consumer price index report, Federal Reserve minutes,...
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
